This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

AAD-2004

GNT Pharma Co., Ltd.

Drug Names(s): AAD-2004

Description: AAD-2004 was developed as a dual function drug to remove excess free radicals and PGE2, the key mediators of nerve injury in Alzheimer's disease (AD), Parkinson's disease (PD), and amyotrophic lateral sclerosis (ALS). AAD-2004 is a potent microsomal prostaglandin E2 synthase-1 (mPGES-1) inhibitor and spin trapping molecule. Anti-symptomatic and disease-modifying potential of AAD-2004 has been verified in animal models of AD, ALS, and PD. AAD-2004 also shows anti-depression effects comparable to fluoxetine.

Deal Structure: In April 2012, Global Neurotech (GNT) Pharma announced a strategic relationship with Toyota Tsusho Corporation (TTC) . TTC will represent GNT Pharma exclusively in Japan in promoting its products and technologies in the area for neurological and inflammatory diseases.


AAD-2004 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug